Overall, we provide molecular and cellular insights into the manipulation of tumor progression by TREM2+ TAMs and propose a valuable approach for remodeling the anti-tumor TME, emphasizing that TREM2 blockade in combination with galectin-3 inhibitors may present a practical strategy for the clinical management of lung cancer or other cancer types. Here, LGALS3 is linked to lung carcinoma.